Evidence map›Paper›PMID 35982133›Full record

ArticleScientific reports2022

Saliva-based SARS-CoV-2 serology using at-home collection kits returned via mail.

Christopher Campbell, Douglas Roblin, Nikhil Padmanabhan, Daniel Romero, Jessica Joe, Lily Fathi, Thomas Whiting, Jared Williamson, Paul Goodwin, Charmaine Mckie and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christopher CampbellMeso Scale Diagnostics, LLC., Rockville, MD, USA. ccampbell@mesoscale.com.
Douglas RoblinMid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, USA.
Nikhil PadmanabhanMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Daniel RomeroMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Jessica JoeMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Lily FathiMid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, USA.
Thomas WhitingMid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, USA.
Jared WilliamsonMid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, USA.
Paul GoodwinMeso Scale Diagnostics, LLC., Rockville, MD, USA.
Charmaine MckieMid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, USA.
Adrienne DenealMid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, USA.
Leslie GreenbergMid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, USA.
George SigalMeso Scale Diagnostics, LLC., Rockville, MD, USA.

Funding

NIAID NIH HHS HHSN272201700013C
6 · The paper itself

Abstract

Serology provides tools for epidemiologic studies, and may have a role in vaccine prioritization and selection. Automated serologic testing of saliva, especially specimens that are self-collected at home and sent to a laboratory via the mail without refrigeration, could be a highly-scalable strategy for population-wide testing. In this prospective study, non-vaccinated patients were recruited after PCR testing to self-collect saliva and return their specimens via mail. Longitudinal specimens were analyzed in order to monitor seroconversion in the weeks after a diagnostic PCR test for SARS-CoV-2. Diverse users self-collected saliva and returned specimens via mail in compliance with shipping regulations. At our pre-established threshold (0.963 AU/mL), salivary IgG reactivity to full-length spike protein achieved 95.8% sensitivity and 92.4% specificity at 2-4 weeks after diagnostic testing, which is comparable to the typical sensitivity and specificity achieved for serum testing. Reactivity to N antigen also was detected with 92.6% sensitivity and 90.7% specificity at 4-8 weeks after diagnostic testing. Moreover, serologic testing for endemic coronaviruses performed in multiplex with SARS-CoV-2 antigens has the potential to identify samples that may require retesting due to effects of pre-analytical factors. The easy-to-use saliva collection kit, coupled with thresholds for positivity and methods of flagging samples for retest, provides a framework for large-scale serosurveillance of SARS-CoV-2.

Indexed as

COVID-19SARS-CoV-2Clinical Laboratory TechniquesHumansPostal ServiceProspective StudiesSalivaSensitivity and Specificity

Identifiers

PMID35982133
PMCPMC9387411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.